Abstract
We investigated the in vivo effect of atorvastatin on bone mineral density (BMD) in ovariectomized (OVX) rats. Eight-week-old female rats underwent either a sham operation or ovariectomy, and treatments with vehicle, atorvastatin, 17β-estradiol (E2) and human parathyroid hormone(1–34) [hPTH(1–34)] were initiated 6 wk after the surgery. E2 (10 µg/kg) treatment for 12 wk significantly increased lumbar BMD (L2–L4), whereas atorvastatin did not affect lumbar BMD. The combination of atorvastatin (2 mg/kg) and E2 significantly enhanced the BMD of lumbar vertebrae (L2–L4) and femoral metaphyseal area (2/10–4/10 segments from the most proximal point) compared to that of either E2 or atorvastatin alone. A low dose 1 µg/kg of hPTH (1–34) did not alter lumbar or femoral BMD, whereas a high dose 17.5 µg/kg of the peptide significantly increased BMD. Concomitant injections of atorvastatin (2 mg/kg) with hPTH(1–34) (1 µg/kg) for 8 wk significantly enhanced the BMD of lumbar vertebrae and the metaphyseal area of the femur in OVX rats. These findings demonstrate that chronic administration of atorvastatin appears to modestly enhance the BMD of the lumbar vertebrae and femoral metaphysis of OVX rats treated with submaximal doses of E2 and hPTH(1–34).
Similar content being viewed by others
References
Riggs, B. L. and Melton, L. J. III (1992). N. Engl. J. Med. 327, 620–627.
Christiansen, C. and Lindsay, R. (1990). Osteoporos. Int. 1, 7–13.
Conference Report (1993). Am. J. Med. 94, 646–650.
Margolis, R. N., Canalis, E., and Partridge, N. C. (1996). J. Clin. Endocrinol. Metab. 81, 872–877.
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., et al. (2001). N. Engl. J. Med. 344, 1434–1441.
Kawane, T., Takahashi, S., Saitoh, H., Okamoto, H., Kubodera, N., and Horiuchi, N. (2002). Horm. Metab. Res. 34, 293–302.
Ma, Y. L., Bryant, H. U., Zeng, Q., et al. (2003). Endocrinology 144, 2008–2015.
Goldstein, J. L. and Brown, M. S. (1990). Nature 343, 425–430.
Maron, D. J., Fazio, S., and Linton, M. F. (2000). Circulation 101, 207–213.
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., and Bernini, F. (1999). Pharmacol. Ther. 84, 413–428.
Casey, P. J. and Seabra, M. C. (1996). J. Biol. Chem. 271, 5289–5292.
Mundy, G., Garrett, R., Harris, S., et al. (1999). Science 286, 1946–1949.
Maeda, T., Kawane, T., and Horiuchi, N. (2003). Endocrinology 144, 681–692.
Maeda, T., Matsunuma, A., Kawane, T., and Horiuchi, N. (2001). Biochem. Biophys. Res. Commun. 280, 874–877.
Fisher, J. E., Rogers, M. J., Halasy, J. M., et al. (1999). Proc. Natl. Acad. Sci. USA 96, 133–138.
van Beek, E., Lowik, C., van der Pluijm, G., and Papapoulos, S. (1999). J. Bone Miner. Res. 14, 722–729.
Wang, G. J., Chung, K. C., and Shen, W. J. (1995). J. Formos. Med. Assoc. 94, 589–592.
Maritz, F. J., Conradie, M. M., Hulley, P. A., Gopal, R., and Hough, S. (2001). Arterioscler. Thromb. Vasc. Biol. 21, 1636–1641.
Mundy, G. R., Chen, D., and Oyajobi, B. O. (2003) In: Primer on the metabolic bone diseases and disorders of mineral metabolism, fifth edition. Favus, M. J. (ed). The American Society for Bone Mineral Research: Washington, DC.
Kimmel, D. B., Bozzato, R. P., Kronis, K. A., et al. (1993) Endocrinology. 132, 1577–1584.
Turner, R. T., Vandersteenhoven, J. J., and Bell, N. H. (1987) J. Bone Miner. Res. 2, 115–122.
Maeda, T., Matsunuma, A., Kurahashi, I., Yanagawa, T., Yoshida, H., and Horiuchi, N. (2004) J. Cell. Biochem. 92, 458–471.
Staal, A., Frith, J. C., French, M. H., et al. (2003). J. Bone Miner. Res. 18, 88–96.
Skoglund, B., Forslund, C., and Aspenberg, P. (2002). J. Bone Miner. Res. 17, 2004–2008.
Meier, C. R., Schlienger, R. G., Kraenzlin, M. E., Schlegel, B., and Jick, H. (2000). JAMA 283, 3205–3210.
Wang, P. S., Solomon, D. H., Mogun, H., and Avorn, J. (2000). JAMA. 283, 3211–3216.
Chung, Y. S., Lee, M. D., Lee, S. K., Kim, H. M., and Fitzpatrick, L. A. (2000). J. Clin. Endocrinol. Metab. 85, 1137–1142.
Edwards, C. J., Hart, D. J., and Spector, T. D. (2000). Lancet 355, 2218–2219.
Rejnmark, L., Buus, N. H., Vestergaard, P., Andreasen, F., Larsen, M. L., and Mosekilde, L. (2002). Eur. J. Clin. Invest. 32, 581–589.
Sirola, J., Honkanen, R., Kroger, H., Jurvelin, J. S., Maenpaa, P., and Saarikoski, S. (2002). Osteoporos. Int. 13, 537–541.
Illingworth, D. R. and Tobert, J. A. (1994). Clin. Ther. 16, 366–385.
Sato, M., Vahle, J., Schmidt, A., et al. (2002). Endocrinology 143, 3230–3242.
Thompson, D. D., Simmons, H. A., Pirie, C. M., and Ke, H. Z. (1995). Bone 17(Suppl.), 125S-133S.
Kalu, D. N., Arjmandi, B. H., Liu, C. C., Salih, M. A., and Birnbaum, R. S. (1994). Bone Miner. 25, 135–148.
Black, A. E., Hayes, R. N., Roth, B. D., Woo, P. and Woolf, T. F. (1999). Drug Metab. Dipos. 27, 916–923.
Shiraishi, A., Takeda, S., Masaki, T., et al. (2000). J. Bone Miner. Res. 15, 770–779.
Kalu, D. N., Liu, C.-C., Hardin, R. R., and Hollis, B. W. (1989). Endocrinology. 124, 7–16.
Colin, E. M., Van Den Bemd, G. J., Van Aken, M., et al. (1999). J. Bone Miner. Res. 14, 57–64.
Kalu, D. N. and Chen, C. (1999). J. Bone Miner. Res. 14, 593–601.
Rejnmark, L., Buus, N. H., Vestergaard, P., et al. (2004). J. Bone Miner. Res. 19, 737–744.
LaCroix, A. Z., Cauley, J. A., Pettinger, M., et al. (2003). Ann. Intern. Med. 139, 97–104.
Montagnani, A., Gonnelli, S., Cepollaro, C., et al. (2003). Bone 32, 427–433.
Corsini, A., Raiteri, M., Soma, M. R., Bernini, F., Fumagalli, R., and Paoletti, R. (1995). Am. J. Cardiol. 13, 21A-28A.
Kureishi, Y., Luo, Z., Shiojima, I., et al. (2000). Nat. Med. 6, 1004–1010.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kawane, T., Terashima, S., Kurahashi, I. et al. Atorvastatin enhances bone density in ovariectomized rats given 17β-estradiol or human parathyroid hormone(1–34). Endocr 24, 121–129 (2004). https://doi.org/10.1385/ENDO:24:2:121
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:24:2:121